je.st
news
Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval
2015-04-27 05:33:40| drugdiscoveryonline Home Page
Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
Tags: fourth
approval
receives
fda
Category:Biotechnology and Pharmaceuticals